The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Akums Drugs will undertake this development and commercialization in India
This product is categorized as antacids, antiflatulents and anti-Ulcerants
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
e brings over 27+ years of rich pharmaceutical experience
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Subscribe To Our Newsletter & Stay Updated
